The Zhitong Finance App learned that on Tuesday, Chinese veterinary vaccine supplier Zhengye Biotech (ZYBT.US) entered the US stock market. As of press release, it had surged more than 22% to 4.88 US dollars. The company's initial public offering of 1.5 million shares is priced at $4 per share. According to reports, Zhengye Biotech was founded in 2004 and focuses on the research, development, manufacture and sale of veterinary vaccines, with a focus on livestock vaccines. Its product portfolio currently includes 43 veterinary vaccines, covering all major vaccines for livestock such as pigs and cows, and it is also developing vaccines for domestic animals such as dogs. Zhengye Biotech's products are sold in 29 provincial regions in China and exported to overseas countries such as Vietnam, Pakistan, and Egypt. According to the data, the company's sales for the 12 months ended December 31, 2023 were US$29 million.

The Zhitong Finance App learned that on Tuesday, Chinese veterinary vaccine supplier Zhengye Biotech (ZYBT.US) entered the US stock market. As of press release, it had surged more than 22% to 4.88 US dollars. The company's initial public offering of 1.5 million shares is priced at $4 per share. According to reports, Zhengye Biotech was founded in 2004 and focuses on the research, development, manufacture and sale of veterinary vaccines, with a focus on livestock vaccines. Its product portfolio currently includes 43 veterinary vaccines, covering all major vaccines for livestock such as pigs and cows, and it is also developing vaccines for domestic animals such as dogs. Zhengye Biotech's products are sold in 29 provincial regions in China and exported to overseas countries such as Vietnam, Pakistan, and Egypt. According to the data, the company's sales for the 12 months ended December 31, 2023 were US$29 million.